Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508

Oncology Group Study ◽

Chop Therapy

Standard CHOP therapy for low (L) or low-intermediate (L-I) risk patients (pts) with aggressive non-Hodgkin's lymphoma (NHL): A multicenter phase II study by Japan Clinical Oncology Group (JCOG 9508)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.6703 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6703-6703

Author(s):

M. Ogura ◽

Y. Kagami ◽

K. Itoh ◽

K. Tobinai ◽

T. Chou ◽

...

Keyword(s):

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Hodgkin's Lymphoma ◽

Oncology Group ◽

Multicenter Phase ◽

Non Hodgkin's Lymphoma ◽

Risk Patients ◽

Chop Therapy

Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)

International Journal of Hematology ◽

10.1007/s12185-010-0712-8 ◽

2010 ◽

Vol 92 (5) ◽

pp. 713-724 ◽

Cited By ~ 13

Author(s):

Michinori Ogura ◽

Kuniaki Itoh ◽

Tomohiro Kinoshita ◽

Haruhiko Fukuda ◽

Takeaki Takenaka ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Clinical Stage ◽

Stage Ii ◽

Newly Diagnosed ◽

Oncology Group ◽

Randomized phase II study of biweekly CHOP anddose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma: Japan Clinical Oncology Group Study 9505

Annals of Oncology ◽

10.1093/annonc/mdf287 ◽

2002 ◽

Vol 13 (9) ◽

pp. 1347-1355 ◽

Cited By ~ 40

Author(s):

K. Itoh ◽

T. Ohtsu ◽

H. Fukuda ◽

Y. Sasaki ◽

M. Ogura ◽

...

Keyword(s):

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Hodgkin's Lymphoma ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized Phase Ii ◽

Non Hodgkin's Lymphoma ◽

Prophylactic Use

Standard CHOP therapy for low (L) or low-intermediate (L-I) risk patients (pts) with aggressive non-Hodgkin's lymphoma (NHL): A multicenter phase II study by Japan Clinical Oncology Group (JCOG 9508)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.6703 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6703-6703

Author(s):

M. Ogura ◽

Y. Kagami ◽

K. Itoh ◽

K. Tobinai ◽

T. Chou ◽

...

Keyword(s):

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Hodgkin's Lymphoma ◽

Oncology Group ◽

Multicenter Phase ◽

Non Hodgkin's Lymphoma ◽

Risk Patients ◽

Chop Therapy

Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705)

Leukemia & Lymphoma ◽

10.3109/10428194.2012.705000 ◽

2012 ◽

Vol 54 (1) ◽

pp. 46-52 ◽

Cited By ~ 4

Author(s):

Michinori Ogura ◽

Kuniaki Itoh ◽

Kenichi Ishizawa ◽

Yukio Kobayashi ◽

Kensei Tobinai ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Stage ◽

Newly Diagnosed ◽

Oncology Group ◽

A Phase II Study of VEPA/FEPP Chemotherapy for Aggressive Lymphoma in Elderly Patients: Japan Clinical Oncology Group Study JCOG9203

International Journal of Hematology ◽

10.1532/ijh97.05084 ◽

2006 ◽

Vol 83 (1) ◽

pp. 55-62 ◽

Cited By ~ 5

Author(s):

Fumi Mizoroki ◽

Yuko Hirose ◽

Masayuki Sano ◽

Haruhiko Fukuda ◽

Kensei Tobinai ◽

...

Keyword(s):

Elderly Patients ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Aggressive Lymphoma ◽

Oncology Group ◽

Phase II Study of Oral Etoposide and Intravenous Irinotecan for Patients with Platinum-resistant and Taxane-pretreated Ovarian Cancer: Japan Clinical Oncology Group Study 0503

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyr201 ◽

2012 ◽

Vol 42 (3) ◽

pp. 222-225 ◽

Cited By ~ 3

Author(s):

K. Matsumoto ◽

N. Katsumata ◽

I. Saito ◽

T. Shibata ◽

I. Konishi ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Oral Etoposide ◽

Oncology Group ◽

Oncology Group Study ◽

Platinum Resistant

Phase II study of rituximab plus high-dose ara-C (HDAC)-containing chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma (MCL): Japan Clinical Oncology Group study (JCOG0406).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8565 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8565-8565

Author(s):

Michinori Ogura ◽

Kensei Tobinai ◽

Taro Shibata ◽

Kiyoshi Ando ◽

Mitsutoshi Kurosawa ◽

...

Keyword(s):

Mantle Cell Lymphoma ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

High Dose ◽

Oncology Group ◽

Oncology Group Study ◽

Mantle Cell

A Phase II Study of Doxifluridine in Elderly Patients with Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG 9410)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyf022 ◽

2002 ◽

Vol 32 (3) ◽

pp. 90-94 ◽

Cited By ~ 8

Author(s):

N. Ikeda

Keyword(s):

Gastric Cancer ◽

Elderly Patients ◽

Advanced Gastric Cancer ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Oncology Group ◽

Phase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)

Annals of Oncology ◽

10.1093/annonc/mds415 ◽

2012 ◽

Vol 23 ◽

pp. ix492 ◽

Cited By ~ 2

Author(s):

H. Daga ◽

H. Murakami ◽

N. Yamamoto ◽

T. Shibata ◽

M. Endo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Oncology Group ◽

Small Cell Lung ◽